Tonix Pharmaceuticals Holding (TNXP) Directors and Executive Officers - CSIMarket
CSIMarket
 
Tonix Pharmaceuticals Holding Corp   (NASDAQ: TNXP)

Tonix Pharmaceuticals Holding Corp

Officers & Directors


SETH LEDERMAN
Chief Executive Officer, President and Director - (Principal Executive Officer)

BRADLEY SAENGER
Chief Financial Officer - (Principal Financial Officer and Principal Accounting Officer)

DAVID GRANGE
Director

JAMES TRECO
Director

ADEOYE OLUKOTUN
Director

MARGARET SMITH BELL
Director

RICHARD BAGGER
Director

CAROLYN TAYLOR
Director

NEWCOMB STILLWELL
Director ,

Tonix Pharmaceuticals Holding Corp currently has 142 employees.

  News about Tonix Pharmaceuticals Holding Corp Key Personnel

Turning the Tide: Tonix Pharmaceuticals Appoints New VP of Market Access Amid Mixed Financial Signals

In a strategic move aimed at bolstering its market presence, Tonix Pharmaceuticals Holding Corp has announced the appointment of Gary Ainsworth as Vice President of Market Access. Mr. Ainsworth, with over two decades of industry experience, is expected to strengthen the company s commercial leadership team and enhance its strategies in navigating the complexities of market access—a critical facet for biopharmaceutical success.This leadership transition arrives at a pivotal moment for Tonix Pharmaceuticals. Over the past 90 days, the company s share price has experienced a significant uptick of 154.54%. This surge reflects a growing investor interest and optimism surrounding the company’s prospects, parti...

Tonix Pharmaceuticals: Strengthening Leadership and Innovating Vaccine Solutions Amidst Global Health Challenges

In an era defined by rapid advancements in biopharmaceuticals, Tonix Pharmaceuticals is emerging as a pivotal player in addressing urgent public health threats, particularly in the realm of infectious diseases. Recently, the company bolstered its leadership team with the strategic appointment of two executives, each bringing decades of expertise in launching and commercializing central nervous system (CNS) products. This is a significant move that underscores Tonix’s commitment to enhancing its operational capacity and strategic direction as it navigates a complex healthcare landscape.One of the foremost public health challenges that has captured global attention is the Mpox outbreak, which has been classi...

Tonix Pharmaceuticals' Tonmya Receives FDA Fast Track Designation for Fibromyalgia Treatment

Tonix Pharmaceuticals Tonmya Granted Fast Track Designation by FDA for Fibromyalgia Treatment
Fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and sleep disturbances, affects approximately 10 million Americans, primarily women. Currently, treatment options for fibromyalgia are limited, and many patients experience unsatisfactory symptom relief. However, there is renewed hope on the horizon as Tonix Pharmaceuticals recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for their drug Tonmya, aimed at addressing this unmet medical need.
Fast Track is a program initiated by the FDA to accelerate the development and review pro...

Tonix Pharmaceuticals Receives FDA Blessing for Innovative PWS Treatment, Battling Financial Headwinds in the Race for a Breakthrough


Tonix Pharmaceuticals Holding Corp has recently achieved a significant milestone in its mission to develop innovative therapies for pediatric diseases. The company announced that it has been granted the highly coveted Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for its novel treatment, TNX-2900, aimed at addressing Prader-Willi Syndrome (PWS). This syndrome, characterized by an insatiable appetite and uncontrollable eating, affects thousands of children worldwide.
TNX-2900 offers a glimmer of hope for PWS patients and their families. Developed as a proprietary magnesium-potentiated formulation of intranasal oxytocin, this treatment harnesses the power of a naturall...






TNXP Management Effectiveness TNXP Revenue per Employee TNXP Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.